Literature DB >> 30548128

Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation.

Ramona Nicolau-Raducu1, Thiago Beduschi2, Rodrigo Vianna2, Christian Diez1, Mahmoud Sleem1, Bhavna P Singh1, Georgia Vasileiou3, Yehuda Raveh1.   

Abstract

Detrimental consequences of hypofibrinolysis, also known as fibrinolysis shutdown (FS), have recently arisen, and its significance in liver transplantation (LT) remains unknown. To fill this gap, this retrospective study included 166 adults who received transplants between 2016 and 2018 for whom baseline thromboelastography was available. On the basis of percent of clot lysis 30 minutes after maximal amplitude, patients were stratified into 3 fibrinolysis phenotypes: FS, physiologic fibrinolysis, and hyperfibrinolysis. FS occurred in 71.7% of recipients, followed by physiologic fibrinolysis in 19.9% and hyperfibrinolysis in 8.4%. Intraoperative and postoperative venous thrombosis events occurred exclusively in recipients with the FS phenotype. Intraoperative thrombosis occurred with an overall incidence of 4.8% and was associated with 25.0% in-hospital mortality. Incidence of postoperative venous thrombosis within the first month was deep venous thrombosis/pulmonary embolism (PE; 4.8%) and portal vein thrombosis/hepatic vein thrombosis (1.8%). Massive transfusion of ≥20 units packed red blood cells was required in 11.8% of recipients with FS compared with none in the other 2 phenotype groups (P = 0.01). Multivariate analysis identified 2 pretransplant risk factors for FS: platelet count and nonalcoholic steatohepatitis/cryptogenic cirrhosis. Recursive partitioning identified a critical platelet cutoff value of 50 × 109 /L to be associated with FS phenotype. The hyperfibrinolysis phenotype was associated with the lowest 1-year survival (85.7%), followed by FS (95.0%) and physiologic fibrinolysis (97.0%). Infection/multisystem organ failure was the predominant cause of death; in the FS group, 1 patient died of exsanguination, and 1 patient died of massive intraoperative PE. In conclusion, there is a strong association between FS and thrombohemorrhagic complications and poorer outcomes after LT.
Copyright © 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2019        PMID: 30548128     DOI: 10.1002/lt.25394

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  4 in total

1.  Detection of early allograft dysfunction at 30 min of reperfusion in liver transplantation: An intraoperative diagnostic tool with real time assessment of graft function.

Authors:  Hunter B Moore; Hillary Yaffe; James J Pomposelli; Michael Wachs; Thomas Bak; Peter Kennealey; Kendra Conzen; Megan Adams; Thomas Pshak; Rashikh Choudhury; Carson Walker; Alexander Schulick; Tanner Ferrell; Michael P Chapman; Elizabeth A Pomfret; Trevor L Nydam
Journal:  Am J Surg       Date:  2020-08-27       Impact factor: 2.565

2.  Functional Testing for Tranexamic Acid Duration of Action Using Modified Viscoelastometry.

Authors:  Tobias Kammerer; Philipp Groene; Sophia R Sappel; Sven Peterss; Paula A Sa; Thomas Saller; Andreas Giebl; Patrick Scheiermann; Christian Hagl; Simon Thomas Schäfer
Journal:  Transfus Med Hemother       Date:  2020-11-09       Impact factor: 3.747

3.  Perioperative coagulofibrinolytic responses in colorectal surgery patients without chemical thromboprophylaxis: a retrospective observational study.

Authors:  Hironori Matsumoto; Kei Ishimaru; Satoshi Kikuchi; Satoshi Akita; Yuji Yamamoto; Motohira Yoshida; Shigehiro Koga; Hiroyuki Egi; Yuji Watanabe
Journal:  Surg Today       Date:  2021-10-25       Impact factor: 2.540

4.  Elevated Pre- and Postoperative ROTEM™ Clot Lysis Indices Indicate Reduced Clot Retraction and Increased Mortality in Patients Undergoing Liver Transplantation.

Authors:  Matthias Hartmann; Benedikt Lorenz; Thorsten Brenner; Fuat H Saner
Journal:  Biomedicines       Date:  2022-08-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.